Company Filing History:
Years Active: 2013-2017
Title: Huaxing Pei: Innovator in Pharmaceutical Compounds
Introduction
Huaxing Pei is a notable inventor based in Carmel, IN (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target various forms of cancer. With a total of 2 patents, his work is paving the way for innovative treatments.
Latest Patents
Pei's latest patents include novel aminopyridyloxypyrazole compounds. These compounds inhibit the activity of transforming growth factor beta receptor 1 (TGFβR1). The pharmaceutical compositions comprising these compounds are designed to treat several types of cancer, including colon cancer, melanoma, hepatocellular carcinoma, renal cancer, glioblastoma, pancreatic cancer, myelodysplastic syndrome, lung cancer, and gastric cancer. Additionally, these compounds may also be used to address fibrosis, particularly liver fibrosis and chronic kidney disease. Another significant patent involves AKT inhibitors, which are formulated to provide pharmaceutical compositions that can be utilized in various therapeutic applications.
Career Highlights
Huaxing Pei is currently employed at Eli Lilly and Company, where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to developing effective treatments for serious health conditions.
Collaborations
Pei collaborates with esteemed colleagues such as Jason Scott Sawyer and William Thomas McMillen. These partnerships enhance the research and development efforts at Eli Lilly and Company.
Conclusion
Huaxing Pei's contributions to pharmaceutical innovations are noteworthy, particularly in the realm of cancer treatment. His patents reflect a dedication to improving patient outcomes through advanced medical research.